The Collateral Benefit of COVID Pandemic: Improved Pharmacological Venous Thromboembolism Prophylaxis Practices in Non-COVID Patients.

Murat ÖzdedeAlper Tuna GüvenDamla Karadeniz GüvenOğuz Abdullah UyaroğluMine Durusu Tanriover

Published in: International journal of general medicine (2023)

We have demonstrated a significant increase in appropriate pharmacologic prophylaxis rates among high-risk patients. Besides all the collateral damage the pandemic has created, it might also have brought collateral benefits with regards to VTE prophylaxis.

Keyphrases

venous thromboembolism
sars cov
end stage renal disease
ejection fraction
newly diagnosed
primary care
healthcare
direct oral anticoagulants
coronavirus disease
prognostic factors
oxidative stress
patient reported outcomes